版本:
中国

BRIEF-Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors

April 11 Bristol-myers Squibb Co

* Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors

* Bristol-Myers - Study to evaluate potential of APX005M + Opdivo to activate antigen-presenting cells in tumor microenvironment to show anti-tumor activity

* Bristol-Myers Squibb- Study to enroll second-line metastatic non-small cell lung cancer patients who have failed prior chemotherapy

* Study to also enroll metastatic melanoma patients who have failed prior I-O therapy Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐